changes lipidemic profile and gut microbiota in a hamster hypercholesterolemic model.
Benef Microbes. 2019 May 28 ;10(5):555-567. Epub 2019 May 15. PMID: 31090460
Hypercholesterolemia is a main risk factor of cardiovascular disease. Probiotics are a safe approach to reduce elevated cholesterol without any deleterious effect to human health.CNCM I-745 probiotic properties are well documented in a context of intestinal dysbiosis. Recentand preclinical studies have suggested its potential effects on dyslipidemia. This is the first controlled study investigating the effects ofCNCM I-745 on lipidemic profile and gut microbiota in a hamster hypercholesterolemic model. Daily administration (3 g/kg) offor 21 or 39 days in hamsters fed a 0.3% cholesterol-diet significantly reduced total plasma cholesterol (<0.001) and increased faecal total cholesterol (<0.05) compared to vehicle-treated animals.significantly modified the gut microbiota composition of the hamster fed a 0.3% cholesterol-diet. These microbial abundancy modifications of the microbiota were correlated to variations of lipidemic values or liver genes expressions. In particularly we found that abundance of g_, the most modified taxon aftertreatment (+236%;<0.05), was correlated to variations in plasmatic lipoproteins level andhepatic gene expression. We also observed a not previously described correlation between the levels of g_in the gut microbiota and total cholesterol plasma concentration. In conclusion, we confirmed the cholesterol-lowering effects ofintake and we demonstrated for the first time theeffect on gut microbiota in the context of hypercholesterolemia in hamsters. Our results provide new insights for a beneficial and safe approach of hypercholesterolemia treatment and could be considered for clinical development, alone or in addition to conventional treatment.